Medtech company with significant Clare presence celebrates major milestone
AEROGEN, Ireland's largest indigenous Medtech company and a World Leader in hospital-based Aerosol drug deliver has marked the production of its 20th million Aerogen Solo product.
Headquartered in Galway, the company has a significant presence at Shannon Industrial Estate. In January 2021 it announced the establishment of a new manufacturing operation at the former Molex facility in the town.
The multi-award-winning Aerogen Solo product is globally used by hospital caregivers to aerosolise drugs for the acutely compromised respiratory patient.
This milestone was jointly celebrated with the company’s 25th anniversary.
Headquartered in Galway with manufacturing in Parkmore and Shannon, Aerogen’s workforce has tripled in the past five years to 500 employees operating in 28 countries. This hugely successful Irish company continues its expansion with 110 new employees introduced in 2023 and a further 50 multi-disciplined positions recently announced.
"I am delighted that Aerogen, an Enterprise Ireland supported company which started its life back in 1997, has now grown to be an international player on the world stage working with and developing lifesaving respiratory devices and clinical products for the health sector globally."
Mr Richmond said the milestone is a testament to the talent of all of Aerogen’s staff.
"The work and dedication of the team was particularly apparent during the pandemic when life-saving products including the Aerogen Solo device were used to treat, and continues to treat, Covid-19 patients worldwide. I would like to congratulate John Power and his team and wish them the very best for the future,” he said.
Leo Clancy, CEO of Enterprise Ireland commented: “I would like to congratulate Aerogen on their 25th anniversary and producing their 20 millionth device. This great Irish medtech company has gone from strength-to-strength, establishing a strong presence in international markets, creating and sustaining high quality jobs here in the West of Ireland, while continuing to invest in innovation. I wish John, Brendan and all the team the very best for the future. Enterprise Ireland looks forward to continuing to work with the company on their growth trajectory, improving the outcomes for so many respiratory patients and their families right across the globe for the next 25 years and beyond.”
John Power, Aerogen CEO and founder, added: "The 20 millionth product is an incredible milestone for us to achieve during our 25 year celebrations. Our journey has been marked by relentless dedication to innovation led and customer-centric solutions and whilst we today rightly celebrate a production milestone, we also reflect on the acutely sick patients those products have played a key role in treating. To be able to impact the clinical outcome for one person is a great privilege, to be involved
in the treatment of 20 million individual patients globally is not alone a huge privilege but also an incredible honour for us all at Aerogen"